cleavage and polyadenylation specific factor 4Genealiases: CPSF30 · NAR · NEB-1 · NEB1
Q-omics provides the consensus-scored CPSF4 profile across patient tissues and cancer cell-line models. CPSF4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CPSF4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CPSF4 protein abundance shows 26,797 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where CPSF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPSF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPSF4 survival associations across molecular data types. CPSF4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPSF4 RNA expression–survival associations across cancer types. High CPSF4 expression shows unfavorable associations in KIRC, KICH, LIHC, ACC and MESO, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for CPSF4 RNA expression.
This table summarizes CPSF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CPSF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPSF4 shows higher tumor expression in COAD, HNSC, KIRC, LIHC, LUAD and KIRP. The COAD box plot shows higher CPSF4 RNA expression in tumor versus normal tissue (log2 FC = +1.305, t-test p < 0.001).
This table shows molecular features associated with CPSF4 in patient tissues and cancer cell lines. In patient samples, CPSF4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CPSF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
